
ARTHROPLASTY
THR: Celecoxib more effective than ibuprofen in prevention of heterotopic bone formation
J Bone Joint Surg Br. 2007 Feb;89(2):155-9.250 patients with severe hip osteoarthritis were randomized to either receive ibuprofen or celecoxib to determine the relative benefits of these drugs in preventing heterotopic ossification following total hip replacement (THR). The results at 3 months post-op indicated that a ten day trial of celecoxib during the post-op period reduced the risk of heterotopic ossification.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in


Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now